Ken Griffin Bristol Myers Squibb CO Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Citadel Advisors LLC holds 6,918,500 shares of BMY stock, worth $400 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
6,918,500
Previous 8,858,400
21.9%
Holding current value
$400 Million
Previous $368 Million
2.68%
% of portfolio
0.07%
Previous 0.08%
Shares
29 transactions
Others Institutions Holding BMY
# of Institutions
2,532Shares Held
1.47BCall Options Held
31.6MPut Options Held
35M-
Vanguard Group Inc Valley Forge, PA189MShares$10.9 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY159MShares$9.18 Billion0.15% of portfolio
-
State Street Corp Boston, MA92.9MShares$5.38 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY77.9MShares$4.51 Billion0.33% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA61MShares$3.53 Billion0.61% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $123B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...